jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Cancer Profile (Men)

Cancer

7 parameters

image

Report in 8Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Multiplex tumor marker test.

₹1,999₹4,359

54% OFF

Parameters

  • List of Tests
    • Alpha Feto Protein (AFP)
    • Beta HCG
    • CA 19.9
    • Carcino Embryonic Antigen (CEA)
    • Free PSA
    • PSA - Total
    • Free PSA / Total PSA

Cancer Profile (Men) - Comprehensive Guide

  • Why is it done?
    • The Cancer Profile (Men) is a comprehensive tumor marker screening panel designed to detect early signs of various cancers in men through measurement of cancer-associated antigens and proteins in blood samples
    • Serves as a screening tool for men at risk of developing prostate cancer, germ cell tumors, hepatocellular carcinoma, colorectal cancer, and gastric cancer
    • Recommended for men over 50 years of age as part of routine health screening, or younger men with family history of cancer
    • Useful for monitoring patients with known cancer history to detect recurrence or treatment response
    • Individual tests work together: PSA markers assess prostate cancer risk, AFP and Beta-HCG detect germ cell tumors, while CEA and CA 19.9 indicate gastrointestinal and other malignancies
    • Provides baseline data for comparison during surveillance of high-risk patients
  • Normal Range
    • Alpha-Fetoprotein (AFP): Normal range 0-11.7 ng/mL (or 0-11.7 µg/L). Values below 10 ng/mL are typically considered negative for malignancy
    • Beta-HCG (Human Chorionic Gonadotropin): Normal range <5 mIU/mL (or <5 IU/L). Values below 1-2 mIU/mL indicate negative result in non-pregnant individuals
    • CA 19.9 (Carbohydrate Antigen 19.9): Normal range <37 U/mL. Values less than 35-40 U/mL are generally considered within normal limits
    • Carcinoembryonic Antigen (CEA): Normal range 0-2.5 ng/mL in non-smokers and 0-5.0 ng/mL in smokers. Values below 2.5 ng/mL indicate normal in most individuals
    • PSA - Total: Normal range 0-4.0 ng/mL (or µg/L). Results below 4.0 ng/mL are typically considered normal; 4.0-10.0 ng/mL is borderline; above 10.0 ng/mL is elevated
    • Free PSA: Normal range typically >25% of total PSA. Free PSA percentage below 25% increases cancer risk probability
    • Free PSA/Total PSA Ratio: Normal ratio >0.25 (or >25%). Ratios below 0.25 suggest higher cancer risk; ratios above 0.25 suggest lower cancer risk
  • Interpretation
    • Alpha-Fetoprotein (AFP): Elevated levels (>11.7 ng/mL) suggest possible germ cell tumors (testicular cancer), hepatocellular carcinoma, or hepatitis. Progressive elevation indicates more advanced disease; serial measurements track tumor burden and treatment response
    • Beta-HCG (Human Chorionic Gonadotropin): Elevated levels (>5 mIU/mL) in men indicate germ cell tumors, particularly non-seminomatous testicular cancer, choriocarcinoma, or other trophoblastic tumors. Level correlates with tumor burden and prognosis
    • CA 19.9: Elevated levels (>37 U/mL) suggest gastric cancer, pancreatic cancer, colorectal cancer, or biliary tract malignancies. Very high levels (>1000 U/mL) typically indicate advanced disease or extensive metastasis
    • Carcinoembryonic Antigen (CEA): Elevated levels (>2.5 ng/mL) indicate colorectal cancer, gastric cancer, pancreatic cancer, or lung cancer. Values are higher in smokers. Serial elevation suggests disease progression or recurrence
    • PSA - Total: Values 4.0-10.0 ng/mL warrant further evaluation with PSA velocity and free PSA percentage; >10.0 ng/mL strongly suggests prostate cancer and mandates biopsy; interpretation varies with age (age-specific PSA cutoffs used)
    • Free PSA: Percentage >25% of total PSA indicates lower cancer probability; <25% suggests higher cancer risk requiring further investigation; <10% indicates significantly elevated cancer risk
    • Free PSA/Total PSA Ratio: Ratio >0.25 (or 25%) suggests benign prostatic hyperplasia rather than cancer; ratio <0.10 indicates high cancer probability; ratio 0.10-0.25 indicates intermediate risk requiring careful monitoring
    • Factors affecting accuracy: Recent ejaculation or prostate trauma can elevate PSA; urinary tract infections increase PSA levels; certain medications (finasteride) lower PSA; benign prostate hyperplasia causes elevation independent of cancer
  • Associated Organs
    • Alpha-Fetoprotein (AFP): Primarily evaluates liver (hepatocellular carcinoma) and testes (germ cell tumors). Associated diseases include viral hepatitis, cirrhosis, hepatic adenoma, and testicular cancer. Complications include metastatic spread and liver failure
    • Beta-HCG: Evaluates testes and related germ cell malignancies. Associated conditions include non-seminomatous testicular cancer, seminoma, choriocarcinoma, and embryonal carcinoma. Complications include testicular atrophy, infertility, and systemic metastasis
    • CA 19.9: Evaluates gastrointestinal tract organs including stomach, pancreas, colon, and biliary system. Associated malignancies include pancreatic adenocarcinoma, colorectal cancer, gastric cancer, and cholangiocarcinoma. Complications include obstruction, jaundice, and metastatic disease
    • Carcinoembryonic Antigen (CEA): Evaluates gastrointestinal organs (colon, rectum, stomach) and respiratory tract. Associated cancers include colorectal cancer, gastric cancer, pancreatic cancer, and lung cancer. Complications include bowel obstruction, bleeding, and pulmonary metastasis
    • PSA - Total: Evaluates prostate gland function and health. Associated diseases include benign prostate hyperplasia, prostatitis, urinary tract infections, and prostate cancer. Complications include urinary obstruction, urinary retention, erectile dysfunction, and urinary incontinence
    • Free PSA and Free PSA/Total PSA Ratio: Specifically assess prostate cancer risk by evaluating PSA forms. Low free PSA percentage indicates higher malignancy probability. Associated complications of prostate cancer include bone metastasis, lymph node involvement, and systemic dissemination
  • Follow-up Tests
    • Elevated AFP: Ultrasound or CT imaging of liver and abdomen; testicular ultrasound for germ cell tumors; liver function tests (LFTs); hepatitis serologies; consider MRI for further characterization; biopsy may be indicated
    • Elevated Beta-HCG: Testicular ultrasound (standard imaging for germ cell tumors); CT chest and abdomen for staging; consideration of repeat beta-HCG measurement; possible tumor biopsy; consultation with oncology regarding chemotherapy protocols
    • Elevated CA 19.9: CT or MRI imaging of abdomen and pelvis; colonoscopy if colorectal cancer suspected; upper endoscopy for gastric assessment; endoscopic ultrasound (EUS); liver function tests; possible biopsy for histological confirmation
    • Elevated CEA: Colonoscopy for colorectal cancer screening; chest X-ray or CT chest for lung metastasis; abdominal imaging; upper GI endoscopy if gastric cancer suspected; carcinoembryonic antigen monitoring every 3-6 months during surveillance
    • Elevated PSA or Abnormal Free PSA: Digital rectal examination (DRE); transrectal ultrasound (TRUS); prostate biopsy (12-core minimum); MRI-guided biopsy for better targeting; PSA velocity assessment over 12-24 months; consider repeat PSA testing
    • Monitoring frequency: Annual screening for men 50-69 with normal results; every 2-3 years for men 40-49 at increased risk; baseline and repeat every 3 months during active treatment; post-treatment surveillance every 3-6 months for 2 years, then annually
    • Complementary tests: Complete metabolic panel (CMP) and liver function tests; tumor-associated glycoprotein 72 (TAG-72); additional molecular markers; genetic testing for hereditary cancer syndromes; imaging studies per oncology recommendation
  • Fasting Required?
    • Fasting: No - The Cancer Profile (Men) does not require fasting. Blood samples can be collected at any time of day regardless of meal consumption
    • PSA-specific preparation: Avoid ejaculation for 48 hours prior to PSA testing for most accurate results; avoid vigorous rectal examination within 48-72 hours prior to testing; do not cycle or engage in strenuous activity that puts pressure on the perineal area for 48 hours before testing
    • Medications: No specific medications need to be discontinued; however, inform provider about all current medications including finasteride (Proscar) or dutasteride (Avodart) as these lower PSA levels; report recent antibiotic use within past month as this may affect results
    • Timing considerations: Avoid testing within 48 hours of urinary catheterization, urinary tract infection symptoms, or cystoscopy; wait 48 hours after urinary tract infection treatment completion; schedule testing at consistent time of day if possible for serial monitoring
    • General preparation: Arrive well-hydrated; bring photo identification and insurance information; inform phlebotomist about recent illness or fever; notify staff of any bleeding disorders or anticoagulant use; wear loose, comfortable clothing for easy blood draw access
    • Sample collection: Single blood draw via venipuncture; approximately 5-10 mL of blood collected in appropriate collection tubes; samples properly labeled with patient identifiers; specimens handled per laboratory protocols to ensure accuracy

How our test process works!

customers
customers